Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Ultragenyx Pharmaceutical agrees to sell its Rare Pediatric Disease Priority Review Voucher, earned for Genglycos, for $210 million, Viatris enters a definitive agreement to acquire Pacira BioSciences and its non-opioid pain franchise for $1.65 billion, and Peter Young surveys a biopharma industry steadied by improving financing and M&A activity even as policy uncertainty and patent expirations persist.

Ultragenyx Pharmaceutical has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $210 million, a voucher earned from FDA’s approval of Genglycos (pariglasgene brecaparvovec-opnr), the first treatment to target the underlying cause of glycogen storage disease type Ia rather than just its symptoms. Chief financial officer Howard Horn says monetizing the voucher provides significant non-dilutive capital to advance the company’s rare-disease pipeline and its path to profitability.

Viatris has entered a definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash, a deal valued at $1.65 billion, through a tender offer followed by a second-step merger expected to close by the end of 2026. The acquisition adds Pacira’s non-opioid pain therapies Exparel and Zilretta to Viatris’s portfolio, and chief executive officer Scott Smith calls the deal an important step in building Viatris’s innovative medicines business.

Finally, Peter Young writes that improved financing conditions and accelerating M&A are creating new opportunities across pharma and biotech, even as policy uncertainty, patent expirations, and persistent funding pressures continue to shape the outlook. Young argues that the first half of 2026 broke from past trends in financing, M&A, and the stock market in ways that only make sense once the underlying drivers are examined.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.